We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Panel Urges Coverage for PET in Breast Cancer

Jan 1, 2002
Volume: 
11
Issue: 
1
  • Breast Cancer

WASHINGTON—A federal panel has recommended that the Centers for
Medicare and Medicaid Services (CMS) cover the use of positron emission
tomography (PET) as an adjunct to standard staging tests in detecting
locoregional or distant metastases recurrence in some patients when results
from other tests are inconclusive.

In doing so, the executive committee of the CMS Medicare Coverage Advisory
Committee (MCAC) affirmed a series of decisions made by the MCAC’s diagnostic
imaging panel about the use of PET in breast cancer patients. All but one of
the imaging panel’s decisions were negative.

At its June 2001 meeting, the diagnostic imaging panel voted that inadequate
evidence existed for improved health outcomes to support Medicare coverage of
PET in breast cancer in five areas: (1) To decide whether to perform a biopsy
in patients with an abnormal mammogram or palpable mass, (2) to detect breast
cancer in patients with low-suspicion findings on mammography and other routine
imaging procedures, (3) to decide whether to perform axillary node dissection,
(4) to use as a replacement for or adjunct to standard staging tests in looking
for locoregional or distant metastases recurrence, and (5) to evaluate tumor
response to different chemotherapeutic agents.

Two New Studies

The imaging panel’s decision to support PET as an adjunct in patients with
known or suspected recurrent breast cancer hinged on a re-evaluation of the
data. At its meeting, the group received a technology assessment of the
published literature, which found inadequate evidence to support PET for the
diagnosis of recurrent breast cancer.

After an extensive discussion, the panel voted 5 to 0, with one abstention,
to recommend PET coverage for that purpose.

When the executive committee met, Peter Conti, MD, of the University of
Southern California, speaking on behalf of the Society of Nuclear Medicine and
the American College of Radiology, urged ratification of the imaging panel’s
decision on PET.

Pages

  • 1
  • 2
  • next ›
  • last »

Related Articles

  • Prognostic Tool Can Guide Extended Endocrine Therapy in ER+ Breast Cancer
  • Forecasting PARP Inhibitor Resistance in Breast Cancer Patients
  • OncoMasTR Assay May Help Some Breast Cancer Patients Avoid Chemo
  • RAD51 Linked With PARP Inhibitor Resistance in BRCA-Mutated Breast Cancer
  • HER2+ Breast Cancer Subtypes Resistant to TKIs Through Differing Mechanisms

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.